3D bioprinting has advanced significantly over the past decade. The sector has quickly become one of the leading segments in the 3D printing industry when it comes to innovation. Furthermore, the global bioprinting market is expected to reach over $4 billion by 2027.
Bioprinting utilizes proteins, living cells, and biomaterials to create biological materials. 3D printing in general distributes different materials left and right, up and down, and backward and forwards, to print an item layer by layer. 3D bioprinting uses living cells and biomaterials to print living structures layer by layer to create a natural living product. Therefore, 3DV bioprinters can build complex structures such as blood vessels and skin tissue.
Previously, most bioprinting applications were used in the medical industry only. However, more and more industries are looking into 3D Bioprinting for innovative solutions. The reason for this is that 3D bioprinters have become a lot more sophisticated. They are able to deliver cells with high survivability and high precision. This is why many biotech companies, laboratories, hospitals, and universities around the world are exploring this field.
3D bioprinting has become a very hot trend for many industries. This is because it offers a precise and controlled layer-by-layer assembly of biomaterials in whatever 3D pattern desired. The capabilities of 3D bioprinting are vast so industries not just in medicine should be looking to incorporating this innovative technology.
3D bioprinting allows you to print biomedical parts that have the same properties as natural tissues. This is one of the reasons why 3D bioprinting is considered a crucial technology for the future of medicine. The ultimate goal is to eventually print a fully functional human organ. As the demand for organ transplants continues to grow every year, the solution that 3D bioprinting can bring becomes critical. Many researchers in the 3D bioprinting industry feel that within 20 years, transplant waiting lists will no longer exist. It is estimated that over 114,000 patients are waiting for an organ transplant in the United States. With 3D bioprinting technology, patients will have access to an organ that would be created from the very cells of their body. Therefore, there will be no risk of the organ being rejected by the body.
Rokit has signed a term sheet with a Dubai based venture capital company to...